By Reed McLaughlin, Anju Software
Drug development is slow and costly, and once the medicine is approved, companies are eager to reap their ROI. They may hesitate to spend even more money on medical affairs and information platforms that they believe do not add value. In the past, providing medical information to patients and HCPs meant investing in expensive call centers with dedicated staff to respond to patient inquiries. Also, companies would need more systems and personnel to disseminate the information if they wanted to use the data gathered at call centers to track trends. Investing in call centers and data management systems ate into companies’ ROI after their drug went to market.
However, cutting-edge medical affairs and information platforms require minimal staff time and offer streamlined data access. They respond to inquiries from patients and medical providers, disseminate the answers to the questions, and capture data to deliver insights to organizations to help guide decisions or flag inconsistencies. These platforms also empower HCPs and patients to find the right information quickly and easily and get help when they need it. A state-of-the-art system can increase efficiency and ROI by providing valuable data insights and superior customer service.